62 reports

  • GLOBAL STD TESTING MARKET BY TESTING DEVICES

COBAS HPV TESTS COBAS AMPLISCREEN HIV- ## TEST, V##. ## COBAS AMPLIPREP/ COBAS TAQMAN HIV-## TEST IT IS A PCR TEST FOR THE DETECTION OF HIV-## RNA IN HUMAN PLASMA.

  • Sexually Transmitted Disease
  • World
  • bioMerieux S.A.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.

The RNA based therapies should advance the prospects of new anti-HPV treatments to improve the disease.

  • Infectious Disease
  • Pathology
  • Sexually Transmitted Disease
  • Vaccine
  • World
  • RADIOGRAPHIC TEST

Recently FISH technology has been combined with flow cytometry to allow for rapid examination of RNA expression in individual cells.

  • Sexually Transmitted Disease
  • World
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Inc. Hologic, Inc.
  • provides an overview of Qiagen's key marketed HPV & EBV Tests products.

Qiagen' s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue.

  • In Vitro Diagnostic Reagent
  • Sexually Transmitted Disease
  • Hologic, Inc.
  • QIAGEN N.V.
  • Roche Group
  • OTHER PROMINENT VENDORS

ASSESSMENT ASSESSMENT Source: Technavio Impact ## Low; ## High Roche Diagnostics, one of the subsidiaries of F.

  • Sexually Transmitted Disease
  • Abbott Laboratories, Inc.
  • Hologic, Inc.
  • QIAGEN N.V.
  • Roche Group

Other ##-FU metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.

  • Sexually Transmitted Disease
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

You can easily book an appointment with one online.

  • Sexually Transmitted Disease
  • World
  • Forecast
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche Ltd.

Both DNA and RNA viruses have been shown to be capable of causing cancer in humans.

  • Sexually Transmitted Disease
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Market segmentation by application

You can easily book an appointment with one online.

  • Sexually Transmitted Disease
  • United States
  • Abbott Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Roche Group

TLR## AGONIST RNA POLYMERASE INHIBITOR LURBINECTEDIN SD-## PHARMA MAR SA DYNAVAX TECHNOLOGIES CORP SELECTIVELY BLOCK THE ELONGATION PHASE OF MESSENGER RNA SYNTHESIS PERFORMED BY RNA POLYMERASE II.

  • Sexually Transmitted Disease
  • Japan
  • United States
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • ALL DIAGNOSTICS*

MOLECULAR HISTOLOGY AND CYTOLOGY ## JUNE 2015, BECKMAN COULTER WAS AWARDED THE CE MARK FOR ITS DXN VERIS HCV AND DXN VERIS HIV-## ASSAYS, QUANTITATIVE TESTS FOR HEPATITIS C VIRUS RNA AND HIV-## RNA VIRAL LOAD, RESPECTIVELY, IN HUMAN PLASMA.

  • Sexually Transmitted Disease
  • United States
  • NanoString Technologies, Inc.
  • QIAGEN N.V.
  • Roche Group

Nine of the patients experienced improvement in their HPV## infection, and viral RNA clearance was associated with lesion regression in seven patients.

  • Sexually Transmitted Disease
  • World
  • Altor BioScience Corporation
  • GlobeImmune, Inc.
  • Merck & Co., Inc.
  • Clinical Trial profile. 42 Trial Title
  • Clinical Trial profile. 2 Trial Title

The prominent features of this report are - ##.

  • Pharmaceutical
  • Sexually Transmitted Disease
  • World
  • Product Initiative
  • Daiichi Sankyo Company
  • RXP-2177
  • GONORRHEA - PIPELINE BY MERCK & CO INC, H1 2019

Microbiotix RNA-dependent RNA polymerase is HCV NS##B, used for the replication of the viral genome.

  • Antibiotic Resistance
  • Sexually Transmitted Disease
  • United States
  • Product Initiative
  • Cempra, Inc.
  • Clinical Trial profile. 65 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Pharmaceutical
  • Sexually Transmitted Disease
  • World
  • Product Initiative
  • Gonorrhea - Pipeline by Recce Ltd, H2 2018
  • Gonorrhea - Pipeline by Microbiotix Inc, H2 2018

Microbiotix RNA-dependent RNA polymerase is HCV NS##B, used for the replication of the viral genome.

  • Infectious Disease
  • Sexually Transmitted Disease
  • United States
  • Product Initiative
  • Cempra, Inc.
  • APTAMER TO TARGET HPV E7 PROTEIN FOR CERVICAL CANCER - DRUG PROFILE
  • MEDI-0457 - DRUG PROFILE

Peak mean/ median antibody responses to HPV## E## and HPV## E## antigens for ## evaluable pts were ##:##/ ##:## and ##:##/ ##:##, respectively.

  • Hospital
  • Sexually Transmitted Disease
  • Therapy
  • Vaccine
  • Advaxis, Inc.
  • Human Papillomavirus Protein E6 (E6) - Drug Profiles

Peak mean/ median antibody responses to HPV## E## and HPV## E## antigens for ## evaluable pts were ##:##/ ##:## and ##:##/ ##:##, respectively.

  • Immunotherapy
  • Sexually Transmitted Disease
  • United States
  • World
  • Inovio Pharmaceuticals, Inc.
  • TVGV-1 - DRUG PROFILE

Treatment-related AEs were grade ## fatigue (##/ ##) and rash (##/ ##).

  • Monoclonal Antibody
  • Sexually Transmitted Disease
  • North America
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Trials conducted by companies in Phase III, Phase II and Phase I stand at ##, ## and ## respectively.

  • Clinical Trial
  • Infectious Disease
  • Sexually Transmitted Disease
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • HIV AIDS
  • Sexually Transmitted Disease
  • Merck & Co., Inc.
  • ABN-301 - DRUG PROFILE
  • ONCOLYTIC VIRUS TO TARGET E6/E7 FOR HPV ASSOCIATED HEAD AND NECK CANCER - DRUG PROFILE

In June 2014, Duke University filed a patent application (PCT/ US2014/ ##) entitled " RNA-guided gene editing and gene regulation. "

  • Cancer
  • Sexually Transmitted Disease
  • United States
  • Company
  • Product Initiative
  • APTAMER TO TARGET HPV E7 PROTEIN FOR CERVICAL CANCER - DRUG PROFILE
  • Human Papillomavirus Protein E7 (E7) - Drug Profiles

Peak mean/ median antibody responses to HPV## E## and HPV## E## antigens for ## evaluable pts were ##:##/ ##:## and ##:##/ ##:##, respectively.

  • Immunotherapy
  • Sexually Transmitted Disease
  • United States
  • Product Initiative
  • Advaxis, Inc.
  • TVGV-1 - Drug Profile

TVGV-## has completed a dose escaltion Phase ## study.

  • Immunotherapy
  • Sexually Transmitted Disease
  • Therapy
  • Vaccine
  • CEL-SCI Corporation

Similarly, the Universities' portfolio in Phase I, Preclinical and Discovery stages comprises ##, ## and ## molecules, respectively.

  • Infectious Disease
  • Sexually Transmitted Disease
  • United States
  • Product Initiative
  • Cempra, Inc.
  • Target

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Sexually Transmitted Disease
  • Therapy
  • GlaxoSmithKline plc
  • TVGV-1 - DRUG PROFILE

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Cancer
  • Chemotherapy
  • Sexually Transmitted Disease
  • Therapy
  • United States
  • TVGV-1 - DRUG PROFILE
  • ABN-301 - DRUG PROFILE

STP-## siRNA works by sticking to the messenger RNA (mRNA) that carries the gene' s code to the cell' s protein-making machinery and ensuring that enzymes cut the mRNA at a specific spot.

  • Cancer
  • Immunotherapy
  • Sexually Transmitted Disease
  • Therapy
  • Advaxis, Inc.
  • TVGV-1 - Drug Profile

TVGV-## has completed a dose escalation Phase ## study.

  • Pharmaceutical
  • Sexually Transmitted Disease
  • Vaccine
  • United States
  • CEL-SCI Corporation
  • Clinical Trial profile. 23 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Sexually Transmitted Disease
  • World
  • Product Initiative